Category: Society & Economics Key figures: Alberto Contador (winner); Cadel Evans (runner-up); Levi Leipheimer (third); Alexander Vinokourov and Michael Rasmussen (removed amid doping); the UCI and ASO (governing and organizing bodies)
Summary
The 94th Tour de France ran from July 7 to July 29, 2007, covering 3,570 kilometers (2,218 miles) across 20 stages and two rest days. It was won by Alberto Contador of the Discovery Channel team, who secured the yellow jersey (general classification) and the white jersey (best young rider) in one of the most scandal-riddled editions in the race’s 104-year history.
Race Outcome and Contador’s Victory
Contador, 24 years old at the time of his victory, finished with a total time of 91 hours 00 minutes 26 seconds, edging Australian Cadel Evans (Predictor–Lotto) by 23 seconds — the slimmest Tour margin since Greg LeMond’s 8-second victory over Laurent Fignon in 1989. Discovery Channel teammate Levi Leipheimer of the United States finished third, 31 seconds behind Contador. German climbing specialist Andreas Klöden (Astana) finished fourth at 1 minute 13 seconds.
Contador took command of the race at the Col d’Aubisque in Stage 16 and defended his lead through the Alps. His combination of exceptional climbing ability, a controlled time-trial capability, and tactical composure under pressure distinguished him from rivals who seemed more susceptible to the race’s pressure and uncertainty. The victory — his first Tour de France title — made Contador the first Spanish winner since Miguel Indurain’s fifth and final consecutive victory in 1995.
The Doping Scandals
The 2007 race was defined as much by its exclusions as by its competition:
Alexander Vinokourov — the Kazakhstani race favorite and pre-race co-leader with Rasmussen at various stages — was removed on Stage 15 (July 24) after testing positive for homologous blood transfusion (a process of re-infusing another person’s blood to boost oxygen-carrying capacity). Vinokourov’s Astana team, including Klöden, withdrew collectively. Blood transfusion had been prohibited since 1986, but detection methods were only recently refined enough to identify homologous (as opposed to autologous) transfusion.
Michael Rasmussen of Denmark (Rabobank) held the yellow jersey for eight stages and was the virtual race leader on Stage 16 when his own team pulled him from the competition — not for a positive test, but for misleading the UCI about his training whereabouts prior to the Tour, which had caused him to miss mandatory out-of-competition tests. Rasmussen was initially suspended and later, in 2013, admitted to systematic doping from 1998 through 2010.
Additional withdrawals further depleted the peloton: Cristian Moreni (Cofidis) was arrested for doping and his team withdrew entirely; Iban Mayo (Saunier Duval) returned a positive EPO test. Four teams and multiple riders left the race under doping shadows.
The wave of expulsions during the race itself was unprecedented in the modern Tour and provoked extensive commentary about cycling governance, the UCI’s regulatory framework, and the culture of team-level compliance with doping.
Significance
The Armstrong Succession Problem
Lance Armstrong’s retirement after his seventh consecutive Tour victory in 2005 had left the race without its dominant figure and its associated American commercial momentum. The 2006 Tour had been won by Óscar Pereiro only after Floyd Landis’s initial victory was voided — Landis tested positive for synthetic testosterone and was stripped of the title in September 2007, the same month the 2007 Tour ended. This meant that by the conclusion of the 2007 race, the two most recent finishers’ titles were both under doping clouds, and cycling’s credibility with broadcasters, sponsors, and fans was at a low ebb.
Institutional Reckoning
The 2007 Tour accelerated pressure on cycling’s governing body, the Union Cycliste Internationale (UCI), and on race organizer ASO (Amaury Sport Organisation) to adopt more effective anti-doping measures. The biological passport program — a longitudinal monitoring approach that tracks athletes’ blood values over time to detect abnormal patterns — was piloted more aggressively in subsequent years and became a cornerstone of anti-doping strategy across multiple sports.
The scandal also intensified the debate over team liability: should entire teams be penalized for individual violations? Astana’s withdrawal following Vinokourov’s positive — a decision taken by the UCI and ASO — set a precedent that reappeared in subsequent years, including when Astana was initially excluded from the 2008 Tour.
Contador’s Legacy — and its Complications
Contador went on to become one of the era’s most dominant grand-tour cyclists, winning the 2009 and 2010 Giro d’Italia, the 2007, 2009, and 2010 Tour de France (the latter two later stripped), and the 2008 and 2012 Vuelta a España. His 2010 Tour de France victory was annulled and he received a two-year ban (backdated to 2011–2013) after traces of clenbuterol — a prohibited bronchodilator — were found in his samples; Contador maintained the contamination came from tainted beef consumed during the race, a defense ultimately rejected by the Court of Arbitration for Sport in February 2012.
The 2007 Tour victory was not retroactively stripped, but the revelations surrounding Contador’s career cast a retrospective shadow over the entire era’s competitive integrity. His 2007 win remains recognized in the official record.
Cultural and Economic Dimensions
The Tour de France, with roughly 15 million roadside spectators annually and television audiences in the hundreds of millions across Europe, is among the world’s most-watched annual sporting events. The 2007 scandal damaged advertising revenues and sponsor commitments at the team level; several major sponsors publicly reconsidered or ended cycling partnerships in the immediate aftermath. The controversy contributed to a broader conversation about the economics of professional sports doping — who bears costs when team brands are devalued — that extended into cycling reform discussions through the early 2010s. The same summer, American baseball faced a parallel reckoning as Barry Bonds surpassed Hank Aaron’s career home-run record under the shadow of performance-enhancing-drug allegations, and the year’s crises of institutional credibility extended well beyond sport — most visibly to the September run on Britain’s Northern Rock bank.